Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.
India business grew 11.8% YoY vs mid-single digit industry growth.
The jump in profit is due to the better performance of the API business.
The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
WACKER and Helixmith plan to strategically collaborate on the production of a pDNA gene therapy developed by Helixmith for the treatment of diabetic peripheral neuropathy (DPN).
The company has reported total income of Rs.25699.68 crores during the 9 months period ended December 31, 2020.
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
Lonza maintained business continuity during the COVID-19 pandemic with minimal impacts to operations and supply throughout 2020.
Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.
Subscribe To Our Newsletter & Stay Updated
